SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
NEW YORK, Feb. 27, 2018 -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Details of the presentation are below:
Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Time: 12:30pm PT / 3:30pm ET
A live webcast of the presentation may be accessed at http://wsw.com/webcast/roth32/eyen/ or on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Lee Roth / Tram Bui
The Ruth Group
Phone: 646-536-7012/7035
E-mail: [email protected]/[email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]
